Home > Publications Database > Association of cancer with neuropathological markers of Alzheimer's disease and related dementias. > print

001     282605
005     20251218103445.0
024 7 _ |a 10.1002/dad2.70222
|2 doi
024 7 _ |a pmid:41367891
|2 pmid
024 7 _ |a pmc:PMC12682591
|2 pmc
037 _ _ |a DZNE-2025-01363
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 0
|e First author
245 _ _ |a Association of cancer with neuropathological markers of Alzheimer's disease and related dementias.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765466266_17915
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We assessed associations of cancer diagnoses with neuropathology of Alzheimer's disease (AD) and related dementias.We retrieved 2288 cases from the National Alzheimer Coordinating Center (NACC) cohort with available information on cancer diagnoses and neuropathological scoring of Braak stages, Thal amyloid phases, neuritic plaques, TDP-43 pathology, and Lewy body pathology. We used Bayesian ordinal regression to assess associations of prevalent or incident cancer diagnoses with global cognition and postmortem neuropathological scores.We found extreme evidence (Bayes factor [BF] > 2000) that both prevalent and incident cancer diagnoses were associated with better global cognition, strong evidence (BF = 26) for an association of a prevalent cancer diagnosis with lower TDP-43 pathology, and weak evidence (BF = 3.2) for an association with lower Lewy body pathology.Our data suggest that selective survival and biological effects may contribute to the lower risk of dementia in people with a cancer diagnosis.A prevalent diagnosis of cancer was associated with a lower risk of cognitive decline in older individuals.A prevalent diagnosis of cancer was associated with a lower risk of TDP-43 pathology and Lewy body pathology in older individuals.Effects of cancer on TDP-43 pathology were maintained when controlling for degree of cognitive decline.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease pathology
|2 Other
650 _ 7 |a Braak stages
|2 Other
650 _ 7 |a TDP‐43 pathology
|2 Other
650 _ 7 |a protective factor
|2 Other
700 1 _ |a Akmatov, Manas
|b 1
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 2
|u dzne
700 1 _ |a Junghanss, Christian
|b 3
700 1 _ |a Holstiege, Jakob
|b 4
700 1 _ |a Bohlken, Jens
|b 5
773 _ _ |a 10.1002/dad2.70222
|g Vol. 17, no. 4, p. e70222
|0 PERI:(DE-600)2832898-X
|n 4
|p e70222
|t Alzheimer's & dementia / Diagnosis, assessment & disease monitoring
|v 17
|y 2025
|x 2352-8729
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/282605/files/DZNE-2025-01363.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/282605/files/DZNE-2025-01363.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:282605
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810763
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2024-12-31
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZH DEMENT-DADM : 2022
|d 2024-12-31
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-31
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:09:24Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:09:24Z
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-31
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-08-08T17:09:24Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-31
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZH DEMENT-DADM : 2022
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-31
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)5000067
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21